CCCC Q3 2023 Earnings — C4 Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CCCCC4 Therapeutics, Inc.

$243M

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$11M+63.9% YoY

Gross Profit

$9M82.0% margin

Operating Income

-$28M-251.2% margin

Net Income

-$27M-244.2% margin

EPS (Diluted)

$-0.55

QoQ Revenue Growth

+315.6%

Cash Flow

Operating Cash Flow

-$31M

Free Cash Flow

-$31M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$333M

Total Liabilities

$117M

Stockholders' Equity

$216M

Cash & Equivalents

$61M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$11M	$7M	+63.9%
Gross Profit	$9M	-$23M	+139.6%
Operating Income	-$28M	-$32M	+14.4%
Net Income	-$27M	-$32M	+15.4%